​
​

Sarepta Therapeutics (SRPT) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

SRPT Stock Forecast

Sarepta Therapeutics stock forecast is as follows: an average price target of $169.06 (represents a 52.50% upside from SRPT’s last price of $110.86) and a rating consensus of 'Buy', based on 20 wall street analysts offering a 1-year stock forecast.

SRPT Price Target

The average price target for Sarepta Therapeutics (SRPT) is $169.06 based on 1-year price targets from 20 Wall Street analysts in the past 3 months, with a price target range of $203.00 to $94.00. This represents a potential 52.50% upside from SRPT's last price of $110.86.

SRPT Analyst Ratings

Buy

According to 20 Wall Street analysts, Sarepta Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for SRPT stock is 0 'Strong Buy' (0.00%), 15 'Buy' (75.00%), 4 'Hold' (20.00%), 1 'Sell' (5.00%), and 0 'Strong Sell' (0.00%).

Sarepta Therapeutics Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 07, 2024Brian SkorneyRobert W. Baird$193.00$124.9554.46%74.09%
Nov 07, 2024Kristen KluskaCantor Fitzgerald$167.00$124.9533.65%50.64%
Oct 21, 2024Andrew TsaiJefferies$165.00$127.0829.84%48.84%
Aug 08, 2024Gavin Clark-GartnerEvercore ISI$179.00$136.4031.23%61.46%
Aug 08, 2024Biren AminPiper Sandler$200.00$140.0642.80%80.41%
Aug 08, 2024Gena WangBarclays$203.00$140.0644.94%83.11%
Aug 08, 2024Brian AbrahamsRBC Capital$181.00$140.0629.23%63.27%
Jul 29, 2024Brian AbrahamsRBC Capital$182.00$147.8823.07%64.17%
Jun 27, 2024Kostas BiliourisBMO Capital$200.00$154.7929.21%80.41%
Jun 26, 2024Biren AminPiper Sandler$205.00$156.9130.65%84.92%
Row per page
Go to

The latest Sarepta Therapeutics stock forecast, released on Nov 07, 2024 by Brian Skorney from Robert W. Baird, set a price target of $193.00, which represents a 54.46% increase from the stock price at the time of the forecast ($124.95), and a 74.09% increase from SRPT last price ($110.86).

Sarepta Therapeutics Price Target by Period

1M3M12M
# Anlaysts3323
Avg Price Target$175.00$175.00$178.52
Last Closing Price$110.86$110.86$110.86
Upside/Downside57.86%57.86%61.03%

In the current month, the average price target of Sarepta Therapeutics stock is $175.00, according to 3 Wall Street analysts offering twelve months forecast. The average price target represents a 57.86% increase as opposed to Sarepta Therapeutics's last price of $110.86. This month's average price target is down 0.00% compared to last quarter, and down -1.97% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Nov 07, 2024Cantor FitzgeraldNeutralOverweightUpgrade
Oct 21, 2024Raymond JamesUnderperformUnderperformHold
Oct 21, 2024RBC CapitalBuyBuyHold
Oct 21, 2024Jefferies-BuyInitialise
Oct 04, 2024RBC CapitalNeutralNeutralHold
Oct 04, 2024Piper SandlerUnderperformUnderperformHold
Sep 23, 2024Cowen & Co.BuyBuyHold
Sep 11, 2024BMO CapitalOutperformOutperformHold
Sep 06, 2024Sandler O'NeillSector PerformSector PerformHold
Sep 06, 2024Sandler O'NeilUnderperformUnderperformHold
Row per page
Go to

Sarepta Therapeutics's last stock rating was published by Cantor Fitzgerald on Nov 07, 2024. The company Upgrade its SRPT rating from "Neutral" to "Overweight".

Sarepta Therapeutics Financial Forecast

Sarepta Therapeutics Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Revenue------------$396.78M$331.82M$261.24M$253.50M$258.43M$230.27M$233.49M$210.83M$201.46M$189.41M$164.09M$146.93M$145.14M$143.92M$137.36M$113.67M$100.11M$99.04M
Avg Forecast$983.37M$968.54M$952.16M$932.00M$883.10M$822.71M$764.98M$707.40M$586.12M$407.17M$394.38M$379.52M$387.18M$285.33M$255.99M$241.92M$250.40M$234.52M$220.81M$206.43M$197.97M$178.89M$167.07M$145.81M$150.38M$137.76M$115.66M$234.11M$98.80M$98.48M
High Forecast$1.06B$1.05B$1.03B$1.01B$954.09M$888.85M$826.47M$772.62M$628.74M$407.41M$394.38M$379.52M$393.32M$285.71M$276.57M$261.36M$270.53M$234.52M$220.81M$206.43M$197.97M$178.89M$167.07M$145.81M$150.38M$137.76M$115.66M$234.11M$98.80M$98.48M
Low Forecast$898.69M$885.14M$870.17M$851.75M$807.06M$751.87M$699.11M$639.15M$543.57M$406.94M$394.38M$379.52M$366.05M$284.96M$233.95M$221.09M$228.84M$234.52M$220.81M$206.43M$197.97M$178.89M$167.07M$145.81M$150.38M$137.76M$115.66M$234.11M$98.80M$98.48M
# Analysts3345452712666136665551112111091377986
Surprise %------------1.02%1.16%1.02%1.05%1.03%0.98%1.06%1.02%1.02%1.06%0.98%1.01%0.97%1.04%1.19%0.49%1.01%1.01%

Sarepta Therapeutics's average Quarter revenue forecast for Mar 24 based on 6 analysts is $379.52M, with a low forecast of $379.52M, and a high forecast of $379.52M. SRPT's average Quarter revenue forecast represents a -4.35% decrease compared to the company's last Quarter revenue of $396.78M (Dec 23).

Sarepta Therapeutics EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts3345452712666136665551112111091377986
EBITDA------------$-28.46M$-20.84M$-133.52M$-107.75M$-81.49M$-112.24M$-202.18M$-77.63M$-95.70M$-21.42M$-57.48M$-142.81M$-162.47M$-175.90M$-130.61M$2.77M$-218.40M$-110.31M
Avg Forecast$-639.71M$-630.07M$-619.41M$-606.30M$-574.49M$-535.20M$-497.64M$-460.19M$-381.29M$-264.88M$-256.56M$-94.97M$-251.87M$-185.62M$-166.53M$-101.57M$-125.63M$-154.32M$-145.30M$-108.63M$-130.27M$-117.71M$-109.94M$-116.19M$-98.95M$-90.65M$-76.11M$4.68M$-65.01M$-64.80M
High Forecast$-584.63M$-575.81M$-566.08M$-554.09M$-525.02M$-489.12M$-454.79M$-415.79M$-353.61M$-264.73M$-256.56M$-75.98M$-238.13M$-185.37M$-152.19M$-81.26M$-100.51M$-154.32M$-145.30M$-86.91M$-130.27M$-117.71M$-109.94M$-92.95M$-98.95M$-90.65M$-76.11M$5.61M$-65.01M$-64.80M
Low Forecast$-691.14M$-680.71M$-669.20M$-655.04M$-620.67M$-578.23M$-537.65M$-502.62M$-409.02M$-265.03M$-256.56M$-113.96M$-255.87M$-185.87M$-179.92M$-121.89M$-150.76M$-154.32M$-145.30M$-130.36M$-130.27M$-117.71M$-109.94M$-139.42M$-98.95M$-90.65M$-76.11M$3.74M$-65.01M$-64.80M
Surprise %------------0.11%0.11%0.80%1.06%0.65%0.73%1.39%0.71%0.73%0.18%0.52%1.23%1.64%1.94%1.72%0.59%3.36%1.70%

7 analysts predict SRPT's average Quarter EBITDA for Jun 20 to be $-76.11M, with a high of $-76.11M and a low of $-76.11M. This is -2850.54% lower than Sarepta Therapeutics's previous annual EBITDA (Mar 20) of $2.77M.

Sarepta Therapeutics Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts3345452712666136665551112111091377986
Net Income------------$45.66M$-40.94M$-23.94M$-516.75M$-109.24M$-257.74M$-231.48M$-105.03M$-121.98M$-48.14M$-81.41M$-167.25M$-189.32M$-196.50M$-150.82M$-17.49M$-235.70M$-126.33M
Avg Forecast$310.33M$316.83M$319.30M$321.15M$345.43M$306.37M$290.29M$230.03M$153.69M$-5.99M$-13.01M$-111.22M$6.92M$-122.86M$-178.48M$-118.95M$-135.59M$-115.84M$-104.87M$-127.22M$-118.75M$-169.03M$-122.84M$-136.07M$-170.36M$-161.91M$-163.19M$-29.56M$-170.84M$-128.01M
High Forecast$342.76M$349.94M$352.67M$354.71M$381.53M$338.38M$320.63M$254.71M$194.13M$-5.32M$-11.55M$-88.98M$237.75M$-109.11M$-158.50M$-95.16M$-108.47M$-115.84M$-104.87M$-101.78M$-118.75M$-169.03M$-122.84M$-108.85M$-170.36M$-161.91M$-163.19M$-23.65M$-170.84M$-128.01M
Low Forecast$275.60M$281.37M$283.56M$285.20M$306.76M$272.07M$257.80M$201.97M$92.44M$-6.62M$-14.37M$-133.47M$-92.33M$-135.70M$-197.13M$-142.74M$-162.71M$-115.84M$-104.87M$-152.67M$-118.75M$-169.03M$-122.84M$-163.28M$-170.36M$-161.91M$-163.19M$-35.47M$-170.84M$-128.01M
Surprise %------------6.59%0.33%0.13%4.34%0.81%2.23%2.21%0.83%1.03%0.28%0.66%1.23%1.11%1.21%0.92%0.59%1.38%0.99%

Sarepta Therapeutics's average Quarter net income forecast for Mar 24 is $-111.22M, with a range of $-133.47M to $-88.98M. SRPT's average Quarter net income forecast represents a -343.61% decrease compared to the company's last Quarter net income of $45.66M (Dec 23).

Sarepta Therapeutics SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts3345452712666136665551112111091377986
SG&A------------$131.70M$120.89M$118.56M$110.71M$120.48M$104.79M$154.32M$71.84M$78.06M$61.13M$72.35M$71.13M$86.21M$75.54M$73.85M$82.93M$81.62M$75.64M
Avg Forecast$513.42M$505.68M$497.13M$486.60M$461.07M$429.54M$399.40M$369.34M$306.01M$212.59M$205.91M$47.30M$202.15M$148.97M$133.66M$50.59M$46.95M$122.44M$115.29M$54.11M$103.36M$93.40M$87.23M$57.87M$78.51M$71.93M$60.39M$140.15M$51.59M$51.42M
High Forecast$554.69M$546.33M$537.09M$525.72M$498.13M$464.07M$431.50M$403.39M$328.27M$212.71M$205.91M$56.76M$205.36M$149.17M$144.40M$60.71M$56.34M$122.44M$115.29M$64.93M$103.36M$93.40M$87.23M$69.44M$78.51M$71.93M$60.39M$168.18M$51.59M$51.42M
Low Forecast$469.21M$462.14M$454.32M$444.70M$421.37M$392.56M$365.01M$333.70M$283.80M$212.47M$205.91M$37.84M$191.12M$148.78M$122.15M$40.47M$37.56M$122.44M$115.29M$43.29M$103.36M$93.40M$87.23M$46.30M$78.51M$71.93M$60.39M$112.12M$51.59M$51.42M
Surprise %------------0.65%0.81%0.89%2.19%2.57%0.86%1.34%1.33%0.76%0.65%0.83%1.23%1.10%1.05%1.22%0.59%1.58%1.47%

Sarepta Therapeutics's average Quarter SG&A projection for Mar 24 is $47.30M, based on 6 Wall Street analysts, with a range of $37.84M to $56.76M. The forecast indicates a -64.08% fall compared to SRPT last annual SG&A of $131.70M (Dec 23).

Sarepta Therapeutics EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts3345452712666136665551112111091377986
EPS------------$0.79$-0.46$-0.27$-5.86$-1.34$-2.94$-2.65$-1.20$-1.53$-0.60$-1.02$-2.10$-2.41$-2.50$-1.93$-0.23$-3.08$-1.70
Avg Forecast$3.09$3.15$3.18$3.20$3.44$3.05$2.89$2.29$1.53$-0.06$-0.13$0.01$0.07$-1.22$-1.78$-1.29$-1.47$-1.22$-1.11$-1.31$-1.26$-1.79$-1.30$-1.83$-1.80$-1.71$-1.72$-1.92$-1.81$-1.35
High Forecast$3.41$3.48$3.51$3.53$3.80$3.37$3.19$2.54$1.93$-0.05$-0.11$0.01$2.37$-1.09$-1.58$-1.15$-1.31$-1.22$-1.11$-1.31$-1.26$-1.79$-1.30$-1.83$-1.80$-1.71$-1.72$-1.92$-1.81$-1.35
Low Forecast$2.74$2.80$2.82$2.84$3.05$2.71$2.57$2.01$0.92$-0.07$-0.14$0.01$-0.92$-1.35$-1.96$-1.43$-1.63$-1.22$-1.11$-1.31$-1.26$-1.79$-1.30$-1.83$-1.80$-1.71$-1.72$-1.92$-1.81$-1.35
Surprise %------------11.46%0.38%0.15%4.53%0.91%2.40%2.39%0.91%1.22%0.34%0.79%1.15%1.34%1.46%1.12%0.12%1.71%1.26%

According to 6 Wall Street analysts, Sarepta Therapeutics's projected average Quarter EPS for Mar 24 is $0.01, with a low estimate of $0.01 and a high estimate of $0.01. This represents a -98.37% decrease compared to SRPT previous annual EPS of $0.79 (Dec 23).

Sarepta Therapeutics Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
HEPAHepion Pharmaceuticals$0.69$70.0010044.93%Buy
IOVAIovance Biotherapeutics$8.14$21.00157.99%Buy
TERNTerns Pharmaceuticals$5.60$14.25154.46%Buy
VKTXViking Therapeutics$51.53$102.4098.72%Buy
SRPTSarepta Therapeutics$110.86$169.0652.50%Buy
AKROAkero Therapeutics$30.64$46.0050.13%Buy
PTCTPTC Therapeutics$41.96$46.5010.82%Hold
KRYSKrystal Biotech$178.10$191.007.24%Buy
MDGLMadrigal Pharmaceuticals$317.09$315.75-0.42%Buy

SRPT Forecast FAQ

Is Sarepta Therapeutics a good buy?

Yes, according to 20 Wall Street analysts, Sarepta Therapeutics (SRPT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 15 'Buy' recommendations, accounting for 75.00% of SRPT's total ratings.

What is SRPT's price target?

Sarepta Therapeutics (SRPT) average price target is $169.06 with a range of $94 to $203, implying a 52.50% from its last price of $110.86. The data is based on 20 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Sarepta Therapeutics stock go up soon?

According to Wall Street analysts' prediction for SRPT stock, the company can go up by 52.50% (from the last price of $110.86 to the average price target of $169.06), up by 83.11% based on the highest stock price target, and down by -15.21% based on the lowest stock price target.

Can Sarepta Therapeutics stock reach $200?

SRPT's highest twelve months analyst stock price target of $203 supports the claim that Sarepta Therapeutics can reach $200 in the near future.

What is Sarepta Therapeutics's current price target trend?

3 Wall Street analysts forecast a $175 price target for Sarepta Therapeutics (SRPT) this month, up 57.86% from its last price of $110.86. Compared to the last 3 and 12 months, the average price target increased by 57.86% and increased by 61.03%, respectively.

What are Sarepta Therapeutics's analysts' financial forecasts?

Sarepta Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $3.18B (high $3.44B, low $2.9B), average EBITDA is $-2.068B (high $-1.885B, low $-2.239B), average net income is $1.17B (high $1.3B, low $1.04B), average SG&A $1.66B (high $1.8B, low $1.51B), and average EPS is $11.67 (high $12.89, low $10.34). SRPT's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $3.84B (high $4.14B, low $3.51B), average EBITDA is $-2.495B (high $-2.281B, low $-2.696B), average net income is $1.27B (high $1.4B, low $1.13B), average SG&A $2B (high $2.16B, low $1.83B), and average EPS is $12.62 (high $13.94, low $11.21).

Did the SRPT's actual financial results beat the analysts' financial forecasts?

Based on Sarepta Therapeutics's last annual report (Dec 2023), the company's revenue was $1.24B, beating the average analysts forecast of $1.17B by 6.23%. Apple's EBITDA was $-268M, missing the average prediction of $-706M by -62.04%. The company's net income was $-536M, beating the average estimation of $-413M by 29.66%. Apple's SG&A was $481.87M, missing the average forecast of $535.37M by -9.99%. Lastly, the company's EPS was $-5.8, beating the average prediction of $-4.224 by 37.30%. In terms of the last quarterly report (Dec 2023), Sarepta Therapeutics's revenue was $396.78M, beating the average analysts' forecast of $387.18M by 2.48%. The company's EBITDA was $-28.46M, missing the average prediction of $-252M by -88.70%. Sarepta Therapeutics's net income was $45.66M, beating the average estimation of $6.92M by 559.29%. The company's SG&A was $131.7M, missing the average forecast of $202.15M by -34.85%. Lastly, the company's EPS was $0.79, beating the average prediction of $0.0689 by 1045.92%